title: Can semi-synthetic flavonoids return old microglia to their youthful state?
abstract: A number of studies have indicated that brain inflammation may deteriorate during normal aging and that neuroinflammation is amplified in age-related neurodegenerative diseases. A pivotal role in age-related neuroinflammatory pathologies is attributed to amplified and prolonged activation of microglia. In addition, microglia from the aged brain were reported as senescent displaying many functional impairments. Flavonoids were shown to be promising molecules in modulation of neuroinflammation. Quercetin, a naturally occurring flavonoid, was proven to downregulate inflammatory genes in microglia. Synthetically modified quercetin, 3´-O-(3-chloropivaloyl)quercetin (CPQ), is assumed to posses better biological availability and enhanced antioxidant properties. In the present study, the antineuroinflammatory capacity of CPQ was assessed in BV-2 microglial cells and rat primary microglia. CPQ suppressed more efficiently than its precursor quercetin LPS-induced NO production and iNOS protein expression. However, neither of the compounds tested influenced significantly phagocytosis of BV-2 cells. In addition, CPQ showed a somewhat better suppression of PMA-induced generation of superoxide than did quercetin. Unlike quercetin, CPQ caused a decline in BV-2 microglia proliferation (without any impact on cell viability) along with interference with cell cycle progression. Both compounds tested at 10uM concentration notably enhanced viability of microglia-enriched cultures prepared from 22-month-old rat brains. This was followed by suppression of lipofuscin-like autofluorescence, improvement of lysosomal function and protection of mitochondria in the old microglia. These results can highlight the therapeutic potential of CPQ as a novel antiinflammatory drug in neurodegenerative diseases. In addition, our data suggest that both natural and semisynthetic flavonoids might protect functions of old microglia [VEGA2/0031/12,1/0076/13;APVV-0052-10;ITMS26240220040].
authors.affiliation: Institute of Experimental Pharmacology & Toxicology (Slovak Academy of Sciences), Laboratory of Cell Cultures, Bratislava, Slovak Republic.
authors.forename: Nataša
authors.initials: N
authors.lastname: Mrvová
authors.affiliation: Institute of Medical Biology, Genetics and Clinical Genetics (Comenius University), Faculty of Medicine, Bratislava, Slovak Republic.
authors.forename: Marcela
authors.initials: M
authors.lastname: Kuniaková
authors.affiliation: Institute of Experimental Pharmacology & Toxicology (Slovak Academy of Sciences), Laboratory of Cell Cultures, Bratislava, Slovak Republic.
authors.forename: Vladimír
authors.initials: V
authors.lastname: Knezl
authors.affiliation: Bel/Novamann International Ltd (Eurofins), Bel/Novamann International, Nové Zámky, Slovak Republic.
authors.forename: Miroslav
authors.initials: M
authors.lastname: Veverka
authors.affiliation: Institute of Experimental Pharmacology & Toxicology (Slovak Academy of Sciences), Laboratory of Cell Cultures, Bratislava, Slovak Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Navarová
authors.affiliation: Institute of Experimental Pharmacology & Toxicology (Slovak Academy of Sciences), Laboratory of Cell Cultures, Bratislava, Slovak Republic.
authors.forename: Radomír
authors.initials: R
authors.lastname: Nosál
authors.affiliation: Institute of Experimental Pharmacology & Toxicology (Slovak Academy of Sciences), Laboratory of Cell Cultures, Bratislava, Slovak Republic. Electronic address: exfadada@savba.sk.
authors.forename: Lucia
authors.initials: L
authors.lastname: Racková